MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.31B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 2.12M
Average 5.73M
MNKD Account Payables
Amounts the company owes suppliers for goods and services received.
MannKind CorporationNASDAQ: MNKD
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 220.3% from a year ago
Account payables stood at $16.14M at the end of Q1 FY2026, up 220.3% from a year earlier and up 78.7% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.
Context
- Account payables amounted to 2.2% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +220.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 9.03M USD
- Year-over-year change
- +33.0%
- 4-year CAGR
- +6.8%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.03M | +33.0% |
| FY2024 | 2024-12-31 | 6.79M | -29.1% |
| FY2023 | 2023-12-31 | 9.58M | -13.3% |
| FY2022 | 2022-12-31 | 11.05M | +58.9% |
| FY2021 | 2021-12-31 | 6.96M | — |
Account Payables vs competitors
How MNKD compares with its peers on the latest reported figures
- MNKD's Mar 2026 account payables of $16.14M is the highest of the 6 companies compared; the peer median is $4.4M.
- Its year-over-year change of +220.3% is the highest of 6, against a peer median of +2.0%.
- Account payables amounts to 2.2% of total assets for MNKD, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $16.14M | +220.3% | -6.5% | 2.2% | |
| Mar 2026 | $11.47M | +80.5% | -12.6% | 2.9% | |
SPRYARS Pharmaceuticals, Inc. | Mar 2026 | $4.71M | +14.9% | +51.1% | 1.6% |
| Mar 2026 | $4.4M | +2.0% | +27.2% | 37.0% | |
| Mar 2026 | $1.1M | -54.3% | +18.2% | 0.2% | |
| Mar 2026 | $481K | -5.5% | -41.2% | 0.2% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding MNKD) | $4.4M | +2.0% | +18.2% | 1.6% | |
Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 124.18M | 69.77M | 238.48M | 46.34M | 74.88M |
| Short-term Investments | 79.93M | 101.08M | 56.62M | 150.92M | 96.46M |
| Net Receivables | 4.74M | 16.8M | 14.9M | 11.8M | 38.37M |
| Inventory | 7.15M | 21.77M | 28.55M | 27.89M | 35.31M |
| Other Current Assets | 0 | 25.48M | 34.85M | 31.36M | 46.55M |
| Total Current Assets | 219.49M | 234.9M | 373.39M | 268.31M | 291.58M |
| Property, Plant & Equipment (Net) | 36.61M | 45.13M | 84.22M | 85.37M | 82.42M |
| Goodwill | 0 | 2.43M | 1.93M | 1.93M | 67.6M |
| Intangible Assets | 0 | 1.15M | 1.07M | 5.27M | 5.07M |
| Long-term Investments | 56.62M | 1.96M | 7.16M | 5.48M | 5.01M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8.44M | 9.72M | 7.43M | 27.49M | 340.5M |
| Total Non-current Assets | 101.67M | 60.39M | 101.81M | 125.54M | 500.6M |
| Total Assets | 321.16M | 295.28M | 475.2M | 393.84M | 792.18M |
| Account Payables | 6.96M | 11.05M | 9.58M | 6.79M | 9.03M |
| Short-term Debt | 6.98M | 9.57M | 20M | 0 | 49.24M |
| Tax Payables | 0 | 0 | 1.56M | 49K | 0 |
| Deferred Revenue | 827K | 1.73M | 9.09M | 12.41M | 15.33M |
| Other Current Liabilities | 9.53M | 16.43M | 30.97M | 30.37M | 69.78M |
| Total Current Liabilities | 48.35M | 67.3M | 104.13M | 81.84M | 171.03M |
| Long-term Debt | 281.2M | 273.49M | 248.7M | 36.05M | 320.36M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 24.49M | 37.68M | 69.79M | 51.16M | 39.98M |
| Other Non-current Liabilities | 175.43M | 162.01M | 294.82M | 291.97M | 208.05M |
| Total Non-current Liabilities | 482.16M | 478.52M | 617.24M | 390.82M | 672.17M |
| Total Liabilities | 530.51M | 545.82M | 721.37M | 472.66M | 843.2M |
| Common Stock | 2.52M | 2.64M | 2.7M | 3.03M | 3.08M |
| Retained Earnings | (3.13B) | (3.22B) | (3.23B) | (3.2B) | (3.2B) |
| Accumulated OCI | 0 | 0 | 0 | 1.11M | 115K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (209.35M) | (250.54M) | (246.17M) | (78.82M) | (51.02M) |
| Total Debt | 289.22M | 288.4M | 272.62M | 47.7M | 473.38M |
| Net Debt | 165.04M | 218.63M | 34.14M | 1.36M | 398.5M |
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$4.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.